Cevostamab

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Multiple MyelomaCAR T Cell TherapyRelapsed or Refractory Multiple Myeloma

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

1

Empliciti

Bristol-Myers Squibb

Phase 3

452

Belamaf

GSK

Phase 3

393

TALVEY

Johnson & Johnson

Phase 3

244

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

425

Biaxin

AbbVie

Phase 3

156

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

297

Mozobil

GGenzyme, a Sanofi Company

Phase 3

158

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

99

Granulocyte Colony-Stimulating Factor

Sanofi

Phase 3

610

Daratumumab SC

Johnson & Johnson

Phase 3

5Show 28 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Multiple Myeloma9 trials

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Completed·Roche·Phase 1·NCT03275103·355 enrolled

An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab as Monotherapy and Cevostamab Plus Pomalidomide and Dexamethasone or Cevostamab Plus Daratumumab and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Recruiting·Roche·Phase 1·NCT04910568·186 enrolled

A Phase II, Single Arm, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone in Patients With Multiple Myeloma Who Have Received a Prior BCMA-Targeting CAR T-Cell Therapy

Recruiting·Roche·Phase 2·NCT07825064·45 enrolled

Show 6 more trials

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Patients With Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy

Recruiting·Roche·Phase 3·NCT07555938·380 enrolled

A Platform Study Evaluating the Safety and Efficacy of Multiple Treatments in Patients With Multiple Myeloma

Recruiting·Roche·Preclinical·NCT05583617·200 enrolled

A Phase Ib, Open-Label, Single-Arm, Multicenter Trial Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Patients With Relapsed or Refractory Multiple Myeloma

Active, not recruiting·Roche·Phase 1·NCT06934044·20 enrolled

A Phase Ib, Open-label, Multicenter Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Patients With Relapsed/Refractory Multiple Myeloma

Active, not recruiting·Roche·Phase 1·NCT05646836·90 enrolled

A Phase I/II, Open-Label, Multi-Cohort Study to Evaluate the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen-Exposed Patients With Relapsed/Refractory Multiple Myeloma

Active, not recruiting·Roche·Preclinical·NCT05535244·90 enrolled

Phase 1b Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Patients With Relapsed/Refractory Multiple Myeloma

Recruiting·Regeneron·Phase 1·NCT05137054·317 enrolled

CAR T Cell Therapy1 trial

Cevostamab Following CAR T Cell Therapy for RRMM

Active, not recruiting·UUniversity of Pennsylvania·Phase 2·NCT05801939·30 enrolled

Relapsed Multiple Myeloma1 trial

A Phase Ia/Ib, Multicenter, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RO7875913 in Healthy Volunteers and to Assess Its Preliminary Activity in Combination With Cevostamab In Patients With Relapsed Or Refractory Multiple Myeloma

Active, not recruiting·Roche·Phase 1·NCT07342114·240 enrolled

Lupus Erythematosus, Systemic1 trial

An Open-Label, Multicenter, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cevostamab in Patients With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

Recruiting·Roche·Phase 1·NCT07629583·46 enrolled

Relapsed or Refractory Multiple Myeloma1 trial

An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Patients With Relapsed or Refractory Multiple Myeloma

Recruiting·Roche·Phase 1·NCT05927571·120 enrolled

Details

Drug Info

Related News